OrthoPediatrics (NASDAQ:KIDS) Director David Pelizzon Sells 22,500 Shares of Stock

Key Points

• Director David Pelizzon sold 22,500 OrthoPediatrics shares at an average price of $23.35, generating $525,375. The sale reduced his holdings by 0.34%, leaving him with 6.5 million shares.
• OrthoPediatrics reported quarterly revenue of $70.51 million and an adjusted loss of $0.26 per share, beating analysts’ estimates for both revenue and EPS. Analysts expect a full-year loss of $1.14 per share.
• The stock recently traded at $22.41, while analysts maintained a “Moderate Buy” consensus with an average price target of $26.44; institutional investors own approximately 69.05% of the shares.

OrthoPediatrics Corp. (NASDAQ:KIDS - Get Free Report) Director David Pelizzon sold 22,500 shares of the firm's stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $23.35, for a total transaction of $525,375.00. Following the transaction, the director owned 6,504,133 shares of the company's stock, valued at approximately $151,871,505.55. The trade was a 0.34% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

OrthoPediatrics Trading Down 0.8%

OrthoPediatrics stock traded down $0.18 during trading hours on Friday, reaching $22.41. 129,506 shares of the company's stock were exchanged, compared to its average volume of 173,525. The company has a quick ratio of 2.17, a current ratio of 4.78 and a debt-to-equity ratio of 0.28. The firm's 50 day simple moving average is $21.74 and its 200 day simple moving average is $18.84. OrthoPediatrics Corp. has a twelve month low of $14.42 and a twelve month high of $26.74. The firm has a market capitalization of $585.13 million, a PE ratio of -13.34 and a beta of 0.99.

OrthoPediatrics (NASDAQ:KIDS - Get Free Report) last announced its quarterly earnings data on Tuesday, August 4th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.30) by $0.04. OrthoPediatrics had a negative return on equity of 8.10% and a negative net margin of 15.72%.The company had revenue of $70.51 million for the quarter, compared to the consensus estimate of $68.21 million. Research analysts predict that OrthoPediatrics Corp. will post -1.14 earnings per share for the current year.

Hedge Funds Weigh In On OrthoPediatrics

A number of institutional investors have recently modified their holdings of KIDS. Millennium Management LLC lifted its holdings in shares of OrthoPediatrics by 48.0% in the 4th quarter. Millennium Management LLC now owns 1,396,495 shares of the company's stock worth $24,802,000 after purchasing an additional 452,840 shares in the last quarter. BlackRock Inc. bought a new stake in OrthoPediatrics during the 2nd quarter valued at $24,347,000. Vanguard Group Inc. increased its stake in OrthoPediatrics by 1.1% during the 3rd quarter. Vanguard Group Inc. now owns 961,330 shares of the company's stock valued at $17,813,000 after purchasing an additional 10,927 shares in the last quarter. Granahan Investment Management LLC raised its holdings in OrthoPediatrics by 35.1% during the first quarter. Granahan Investment Management LLC now owns 896,741 shares of the company's stock worth $14,231,000 after buying an additional 232,760 shares during the last quarter. Finally, Wasatch Advisors LP raised its holdings in OrthoPediatrics by 56.6% during the second quarter. Wasatch Advisors LP now owns 515,677 shares of the company's stock worth $9,865,000 after buying an additional 186,357 shares during the last quarter. 69.05% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages have recently commented on KIDS. BTIG Research raised their price objective on shares of OrthoPediatrics from $24.00 to $29.00 and gave the stock a "buy" rating in a research report on Thursday, August 20th. Truist Financial set a $22.00 target price on shares of OrthoPediatrics in a research report on Wednesday, August 5th. TD Cowen reissued a "buy" rating on shares of OrthoPediatrics in a research note on Monday, June 15th. Weiss Ratings raised shares of OrthoPediatrics from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Wednesday, August 5th. Finally, Piper Sandler reiterated an "overweight" rating and set a $25.00 price objective (up from $22.00) on shares of OrthoPediatrics in a report on Wednesday, August 5th. Nine investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, OrthoPediatrics currently has a consensus rating of "Moderate Buy" and a consensus price target of $26.44.

About OrthoPediatrics

OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.

The company's product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source